| Home |
| Lab Members |
| Publications |
| ACHE Knockout |
| Links |
Publications
The articles are listed in chronological order, with the most recent publications at the top.
2005| 2004| 2003| 2002| 2001| 2000| 1999| 1998| 1997| 1996| 1995| 1994| 1993| 1992| 1991| 1990| The 80s| The 70s|
|
2005 Saez-Valero J, de Gracia JA, Lockridge O. Intraperitoneal administration of 340 kDa human plasma butyrylcholinesterase increases the level of the enzyme in the cerebrospinal fluid of rats. Neurosci Lett. 2005 Jul 22-29;383(1-2):93-8. Epub 2005 Apr 12. Oksana Lockridge, Lawrence M. Schopfer, Gail Winger, James H. Woods. Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys; a potential new therapeutic for protection against cocaine and nerve agent toxicity. J Med CBR Def. Volume 3, 2005 Schopfer LM, Voelker T, Bartels CF, Thompson CM, Lockridge O. Reaction kinetics of biotinylated organophosphorus toxicant, FP-biotin, with human acetylcholinesterase and human butyrylcholinesterase. Chem Res Toxicol. 2005 Apr;18(4):747-54. Nachon F, Asojo OA, Borgstahl GE, Masson P, Lockridge O. Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. Biochemistry. 2005 Feb 1;44(4):1154-62. Peeples ES, Schopfer LM, Duysen EG, Spaulding R, Voelker T, Thompson CM, Lockridge O. Albumin, a new biomarker of organophosphorus toxicant exposure, identified by mass spectrometry. Toxicol Sci. 2005 Feb;83(2):303-12. Epub 2004 Nov 3. 2004 Bytyqi AH, Lockridge O, Duysen E, Wang Y, Wolfrum U, Layer PG. Impaired formation of the inner retina in an AChE knockout mouse results in degeneration of all photoreceptors. Eur J Neurosci. 2004 Dec;20(11):2953-62. Adler M, Manley HA, Purcell AL, Deshpande SS, Hamilton TA, Kan RK, Oyler G, Lockridge O, Duysen EG, Sheridan RE. Reduced acetylcholine receptor density, morphological remodeling, and butyrylcholinesterase activity can sustain muscle function in acetylcholinesterase knockout mice. Muscle Nerve. 2004 Sep;30(3):317-27. Lawrence M. Schopfer, Andreea Ticu Boeck, Clarence A. Broomfield, Oksana Lockridge. Mutants of human butyrylcholinesterase with organophosphate hydrolase activity; evidence that His117 is a general base catalyst for hydrolysis of echothiophate. J Med Chem Def. Volume 2, 2004. Wang Y, Schopfer LM, Duysen EG, Nachon F, Masson P, Lockridge O. Screening assays for cholinesterases resistant to inhibition by organophosphorus toxicants. Anal Biochem. 2004 Jun 1;329(1):131-8. Masson P, Bec N, Froment MT, Nachon F, Balny C, Lockridge O, Schopfer LM. Rate-determining step of butyrylcholinesterase-catalyzed hydrolysis of benzoylcholine and benzoylthiocholine. Volumetric study of wild-type and D70G mutant behavior. Eur J Biochem. 2004 May;271(10):1980-90. Wang Y, Boeck AT, Duysen EG, Van Keuren M, Saunders TL, Lockridge O. Resistance to organophosphorus agent toxicity in transgenic mice expressing the G117H mutant of human butyrylcholinesterase. Toxicol Appl Pharmacol. 2004 May 1;196(3):356-66. Masson P, Goldstein BN, Debouzy JC, Froment MT, Lockridge O, Schopfer LM. Damped oscillatory hysteretic behaviour of butyrylcholinesterase with benzoylcholine as substrate. Eur J Biochem. 2004 Jan;271(1):220-34. 2003 Volpicelli-Daley LA, Hrabovska A, Duysen EG, Ferguson SM, Blakely RD, Lockridge O, Levey AI. Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice. Mol Pharmacol. 2003 Dec;64(6):1309-16. Saxena A, Fedorko JM, Vinayaka CR, Medhekar R, Radic Z, Taylor P, Lockridge O, Doctor BP. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases. Eur J Biochem. 2003 Nov;270(22):4447-58. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem. 2003 Oct 17;278(42):41141-7. Epub 2003 Jul 17. Bernard V, Brana C, Liste I, Lockridge O, Bloch B. Dramatic depletion of cell surface m2 muscarinic receptor due to limited delivery from intracytoplasmic stores in neurons of acetylcholinesterase-deficient mice. Mol Cell Neurosci. 2003 May;23(1):121-33. Volpicelli-Daley LA, Duysen EG, Lockridge O, Levey AI. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. Ann Neurol. 2003 Jun;53(6):788-96. Li B, Duysen EG, Volpicelli-Daley LA, Levey AI, Lockridge O. Regulation of muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice. Pharmacol Biochem Behav. 2003 Mar;74(4):977-86. Masson P, Nachon F, Bartels CF, Froment MT, Ribes F, Matthews C, Lockridge O. High activity of human butyrylcholinesterase at low pH in the presence of excess butyrylthiocholine. Eur J Biochem. 2003 Jan;270(2):315-24. 2002 Haux JE, Lockridge O, Casida JE. Specificity of ethephon as a butyrylcholinesterase inhibitor and phosphorylating agent. Chem Res Toxicol. 2002 Dec;15(12):1527-33. Duysen EG, Fry DL, Lockridge O. Early weaning and culling eradicated Helicobacter hepaticus from an acetylcholinesterase knockout 129S6/SvEvTac mouse colony. Comp Med. 2002 Oct;52(5):461-6. Duysen EG, Bartels CF, Lockridge O. Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J Pharmacol Exp Ther. 2002 Aug;302(2):751-8. Sun H, Shen ML, Pang YP, Lockridge O, Brimijoin S. Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther. 2002 Aug;302(2):710-6. Sun H, Pang YP, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol. 2002 Aug;62(2):220-4. Duysen EG, Stribley JA, Fry DL, Hinrichs SH, Lockridge O. Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Brain Res Dev Brain Res. 2002 Jul 30;137(1):43-54. Boeck AT, Schopfer LM, Lockridge O. DNA sequence of butyrylcholinesterase from the rat: expression of the protein and characterization of the properties of rat butyrylcholinesterase. Biochem Pharmacol. 2002 Jun 15;63(12):2101-10. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience. 2002;110(4):627-39. Boeck AT, Fry DL, Sastre A, Lockridge O. Naturally occurring mutation, Asp70his, in human butyrylcholinesterase. Ann Clin Biochem. 2002 Mar;39(Pt 2):154-6. Masson P, Schopfer LM, Bartels CF, Froment MT, Ribes F, Nachon F, Lockridge O. Substrate activation in acetylcholinesterase induced by low pH or mutation in the pi-cation subsite. Biochim Biophys Acta. 2002 Feb 11;1594(2):313-24. Nachon F, Nicolet Y, Viguie N, Masson P, Fontecilla-Camps JC, Lockridge O. Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization. Eur J Biochem. 2002 Jan;269(2):630-7. 2001 Josse D, Lockridge O, Xie W, Bartels CF, Schopfer LM, Masson P. The active site of human paraoxonase (PON1). J Appl Toxicol. 2001 Dec;21 Suppl 1:S7-11. Duysen EG, Li B, Xie W, Schopfer LM, Anderson RS, Broomfield CA, Lockridge O. Evidence for nonacetylcholinesterase targets of organophosphorus nerve agent: supersensitivity of acetylcholinesterase knockout mouse to VX lethality. J Pharmacol Exp Ther. 2001 Nov;299(2):528-35. Masson P, Xie W, Froment MT, Lockridge O. Effects of mutations of active site residues and amino acids interacting with the Omega loop on substrate activation of butyrylcholinesterase. Biochim Biophys Acta. 2001 Jan 12;1544(1-2):166-76. Sun H, El Yazal J, Lockridge O, Schopfer LM, Brimijoin S, Pang YP. Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase. Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J Biol Chem. 2001 Mar 23;276(12):9330-6. Epub 2000 Dec 4. 2000 Li B, Stribley JA, Ticu A, Xie W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs SH, Lockridge O. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem. 2000 Sep;75(3):1320-31. Bartels CF, Xie W, Miller-Lindholm AK, Schopfer LM, Lockridge O. Determination of the DNA sequences of acetylcholinesterase and butyrylcholinesterase from cat and demonstration of the existence of both in cat plasma. Biochem Pharmacol. 2000 Aug 15;60(4):479-87. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, Taylor P, Hinrichs SH, Lockridge O. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther. 2000 Jun;293(3):896-902. Lockridge O, Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology. 2000 Feb-Apr;21(1-2):113-26. Review. Altamirano CV, Bartels CF, Lockridge O. The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme. J Neurochem. 2000 Feb;74(2):869-77. 1999 Altamirano CV, Lockridge O. Conserved aromatic residues of the C-terminus of human butyrylcholinesterase mediate the association of tetramers. Biochemistry. 1999 Oct 5;38(40):13414-22. Masson P, Xie W, Froment MT, Levitsky V, Fortier PL, Albaret C, Lockridge O. Related Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates. Biochim Biophys Acta. 1999 Aug 17;1433(1-2):281-93. Broomfield CA, Lockridge O, Millard CB. Protein engineering of a human enzyme that hydrolyzes V and G nerve agents: design, construction and characterization. Chem Biol Interact. 1999 May 14;119-120:413-8. Xie W, Wilder PJ, Stribley J, Chatonnet A, Rizzino A, Taylor P, Hinrichs SH, Lockridge O. Knockout of one acetylcholinesterase allele in the mouse. Chem Biol Interact. 1999 May 14;119-120:289-99. Josse D, Xie W, Masson P, Schopfer LM, Lockridge O. Tryptophan residue(s) as major components of the human serum paraoxonase active site. Chem Biol Interact. 1999 May 14;119-120:79-84. 42: Josse D, Xie W, Masson P, Lockridge O. Human serum paraoxonase (PON1): identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis. Chem Biol Interact. 1999 May 14;119-120:71-8. Saxena A, Redman AM, Jiang X, Lockridge O, Doctor BP. Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Chem Biol Interact. 1999 May 14;119-120:61-9. Altamirano CV, Lockridge O. Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. Chem Biol Interact. 1999 May 14;119-120:53-60. Masson P, Fortier PL, Albaret C, Clery C, Guerra P, Lockridge O. Structural and hydration changes in the active site gorge of phosporhylated butyrylcholinesterase accompanying the aging process. Chem Biol Interact. 1999 May 14;119-120:17-27. Josse D, Xie W, Renault F, Rochu D, Schopfer LM, Masson P, Lockridge O. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry. 1999 Mar 2;38(9):2816-25. Levitsky V, Xie W, Froment MT, Lockridge O, Masson P. Polyol-induced activation by excess substrate of the D70G butyrylcholinesterase mutant. Biochim Biophys Acta. 1999 Jan 11;1429(2):422-30. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, Lockridge O. An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol. 1999 Jan;55(1):83-91. 1998 Vanlinthout LE, Bartels CF, Lockridge O, Callens K, Booij LH. Prolonged paralysis after a test dose of mivacurium in a patient with atypical serum cholinesterase. Anesth Analg. 1998 Nov;87(5):1199-202. No abstract available. Saxena A, Viragh C, Frazier DS, Kovach IM, Maxwell DM, Lockridge O, Doctor BP. Related Articles, Links The pH dependence of dealkylation in soman-inhibited cholinesterases and their mutants: further evidence for a push-pull mechanism. Biochemistry. 1998 Oct 27;37(43):15086-96. Masson P, Josse D, Lockridge O, Viguie N, Taupin C, Buhler C. Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. J Physiol Paris. 1998 Oct-Dec;92(5-6):357-62. Review. Froment MT, Lockridge O, Masson P. Resistance of butyrylcholinesterase to inactivation by ultrasound: effects of ultrasound on catalytic activity and subunit association. Biochim Biophys Acta. 1998 Sep 8;1387(1-2):53-64. Masson P, Froment MT, Fortier PL, Visicchio JE, Bartels CF, Lockridge O. Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters. Biochim Biophys Acta. 1998 Sep 8;1387(1-2):41-52. 1997 Blong RM, Bedows E, Lockridge O. Tetramerization domain of human butyrylcholinesterase is at the C-terminus. Biochem J. 1997 Nov 1;327 ( Pt 3):747-57. Millard CB, Lockridge O, Broomfield CA. Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase. Biochemistry. 1998 Jan 6;37(1):237-47. Saxena A, Redman AM, Jiang X, Lockridge O, Doctor BP. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry. 1997 Dec 2;36(48):14642-51. Masson P, Fortier PL, Albaret C, Froment MT, Bartels CF, Lockridge O. Aging of di-isopropyl-phosphorylated human butyrylcholinesterase. Biochem J. 1997 Oct 15;327 ( Pt 2):601-7. Masson P, Froment MT, Bartels CF, Lockridge O. Importance of aspartate-70 in organophosphate inhibition, oxime re-activation and aging of human butyrylcholinesterase. Biochem J. 1997 Jul 1;325 ( Pt 1):53-61. Masson P, Legrand P, Bartels CF, Froment MT, Schopfer LM, Lockridge O. Role of aspartate 70 and tryptophan 82 in binding of succinyldithiocholine to human butyrylcholinesterase. Biochemistry. 1997 Feb 25;36(8):2266-77. Lockridge O, Blong RM, Masson P, Froment MT, Millard CB, Broomfield CA. A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase. Biochemistry. 1997 Jan 28;36(4):786-95. 1996 Masson P, Froment MT, Bartels CF, Lockridge O. Asp7O in the peripheral anionic site of human butyrylcholinesterase. Eur J Biochem. 1996 Jan 15;235(1-2):36-48. 1995 Millard CB, Lockridge O, Broomfield CA. Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Biochemistry. 1995 Dec 12;34(49):15925-33. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7187-91. 1994 Jbilo O, Bartels CF, Chatonnet A, Toutant JP, Lockridge O. Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon. 1994 Nov;32(11):1445-57. Kris M, Jbilo O, Bartels CF, Masson P, Rhode S, Lockridge O. Endogenous butyrylcholinesterase in SV40 transformed cell lines: COS-1, COS-7, MRC-5 SV40, and WI-38 VA13. In Vitro Cell Dev Biol Anim. 1994 Oct;30A(10):680-9. Huth JR, Norton SE, Lockridge O, Shikone T, Hsueh AJ, Ruddon RW. Bacterial expression and in vitro folding of the beta-subunit of human chorionic gonadotropin (hCG beta) and functional assembly of recombinant hCG beta with hCG alpha. Endocrinology. 1994 Sep;135(3):911-8. Jbilo O, Toutant JP, Vatsis KP, Chatonnet A, Lockridge O. Promoter and transcription start site of human and rabbit butyrylcholinesterase genes. J Biol Chem. 1994 Aug 19;269(33):20829-37. Masson P, Froment MT, Sorenson RC, Bartels CF, Lockridge O. Mutation His322Asn in human acetylcholinesterase does not alter electrophoretic and catalytic properties of the erythrocyte enzyme. Blood. 1994 May 15;83(10):3003-5. 1993 Huth JR, Perini F, Lockridge O, Bedows E, Ruddon RW. Protein folding and assembly in vitro parallel intracellular folding and assembly. Catalysis of folding and assembly of the human chorionic gonadotropin alpha beta dimer by protein disulfide isomerase. J Biol Chem. 1993 Aug 5;268(22):16472-82. Masson P, Adkins S, Gouet P, Lockridge O. Related Articles, Links Recombinant human butyrylcholinesterase G390V, the fluoride-2 variant, expressed in Chinese hamster ovary cells, is a low affinity variant. J Biol Chem. 1993 Jul 5;268(19):14329-41. Bartels CF, Zelinski T, Lockridge O. Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. Am J Hum Genet. 1993 May;52(5):928-36. 1992 Nogueira CP, Bartels CF, McGuire MC, Adkins S, Lubrano T, Rubinstein HM, Lightstone H, Van der Spek AF, Lockridge O, La Du BN. Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase. Am J Hum Genet. 1992 Oct;51(4):821-8. Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, La Du BN. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet. 1992 May;50(5):1086-103. 1991 Saito K, Thiele DJ, Davio M, Lockridge O, Massey V. The cloning and expression of a gene encoding Old Yellow Enzyme from Saccharomyces carlsbergensis. J Biol Chem. 1991 Nov 5;266(31):20720-4. Allderdice PW, Gardner HA, Galutira D, Lockridge O, LaDu BN, McAlpine PJ. The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics. 1991 Oct;11(2):452-4. McAlpine PJ, Dixon M, Allderdice PW, Lockridge O, La Du BN. The butyrylcholinesterase gene (BCHE) at 3q26.2 shows two RFLPs. Nucleic Acids Res. 1991 Sep 25;19(18):5088. Arpagaus M, Chatonnet A, Masson P, Newton M, Vaughan TA, Bartels CF, Nogueira CP, La Du BN, Lockridge O. Use of the polymerase chain reaction for homology probing of butyrylcholinesterase from several vertebrates. J Biol Chem. 1991 Apr 15;266(11):6966-74. La Du BN, Bartels CF, Nogueira CP, Arpagaus M, Lockridge O. Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing. Cell Mol Neurobiol. 1991 Feb;11(1):79-89. 1990 La Du BN, Bartels CF, Nogueira CP, Hajra A, Lightstone H, Van der Spek A, Lockridge O. Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin Biochem. 1990 Oct;23(5):423-31. Nogueira CP, McGuire MC, Graeser C, Bartels CF, Arpagaus M, Van der Spek AF, Lightstone H, Lockridge O, La Du BN. Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG). Am J Hum Genet. 1990 May;46(5):934-42. Masson P, Chatonnet A, Lockridge O. Evidence for a single butyrylcholinesterase gene in individuals carrying the C5 plasma cholinesterase variant (CHE2). FEBS Lett. 1990 Mar 12;262(1):115-8. Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN, Lockridge O. Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry. 1990 Jan 9;29(1):124-31. Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther. 1990;47(1):35-60. Review. The 80s Chatonnet A, Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J. 1989 Jun 15;260(3):625-34. Review. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, Lockridge O, La Du BN. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989 Feb;86(3):953-7. Lockridge O. Structure of human serum cholinesterase. Bioessays. 1988 Oct;9(4):125-8. Review. McTiernan C, Adkins S, Chatonnet A, Vaughan TA, Bartels CF, Kott M, Rosenberry TL, La Du BN, Lockridge O. Brain cDNA clone for human cholinesterase. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6682-6. Lockridge O, Adkins S, La Du BN. Location of disulfide bonds within the sequence of human serum cholinesterase. J Biol Chem. 1987 Sep 25;262(27):12945-52. Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL. Complete amino acid sequence of human serum cholinesterase. J Biol Chem. 1987 Jan 15;262(2):549-57. La Du BN, Lockridge O. Molecular biology of human serum cholinesterase. Fed Proc. 1986 Dec;45(13):2965-9. Review. Lockridge O, La Du BN. Amino acid sequence of the active site of human serum cholinesterase from usual, atypical, and atypical-silent genotypes. Biochem Genet. 1986 Jun;24(5-6):485-98. Eckerson HW, Oseroff A, Lockridge O, La Du BN. Immunological comparison of the usual and atypical human serum cholinesterase phenotypes. Biochem Genet. 1983 Feb;21(1-2):93-108. Lockridge O, La Du BN. Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase. J Biol Chem. 1982 Oct 25;257(20):12012-8. Lockridge O. Substance P hydrolysis by human serum cholinesterase. J Neurochem. 1982 Jul;39(1):106-10. Meyers C, Lockridge O, La Du BN. Hydrolysis of methylprednisolone acetate by human serum cholinesterase. Drug Metab Dispos. 1982 May-Jun;10(3):279-80. Valentino RJ, Lockridge O, Eckerson HW, La Du BN. Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies. Biochem Pharmacol. 1981 Jun 15;30(12):1643-9. Lockridge O, Mottershaw-Jackson N, Eckerson HW, La Du BN. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J Pharmacol Exp Ther. 1980 Oct;215(1):1-8. The 70s Lockridge O, Eckerson HW, La Du BN. Interchain disulfide bonds and subunit organization in human serum cholinesterase. J Biol Chem. 1979 Sep 10;254(17):8324-30. Poulton TJ, James FM 3rd, Lockridge O. Prolonged apnea following trimethaphan and succinylcholine. Anesthesiology. 1979 Jan;50(1):54-6. Lockridge O, La Du BN. Comparison of atypical and usual human serum cholinesterase. Purification, number of active sites, substrate affinity, and turnover number. J Biol Chem. 1978 Jan 25;253(2):361-6. Lockridge O, Spector EB, Bloom AD. Argininosuccinate synthetase activity in cultured human lymphocytes. Biochem Genet. 1977 Apr;15(3-4):395-407. Spector EB, Lockridge O, Bloom AD. Citrulline metabolism in normal and citrullinemic human lymphocyte lines. Biochem Genet. 1975 Aug;13(7-8):471-85. Walsh C, Lockridge O, Massey V, Abeles R. Studies on the mechanism of action of the flavoenzyme lactate oxidase. Oxidation and elimination with beta-chlorolactate. J Biol Chem. 1973 Oct 25;248(20):7049-54. Lockridge O, Massey V, Sullivan PA. Mechanism of action of the flavoenzyme lactate oxidase. J Biol Chem. 1972 Dec 25;247(24):8097-106. Walsh CT, Schonbrunn A, Lockridge O, Massey V, Abeles RH. Inactivation of a flavoprotein, lactate oxidase, by an acetylenic substrate. J Biol Chem. 1972 Sep 25;247(18):6004-6. Lorand L, Lockridge OM, Campbell LK, Myhrman R, Bruner-Lorand J. Transamidating enzymes. II. A continuous fluorescent method suited for automating measurements of factor XIII in plasma. Anal Biochem. 1971 Nov;44(1):221-31. |